Form 4: Lineage Cell Therapeutics Executive Reports Stock Transactions
SEC Form 4 Filing
General Counsel George A. Samuel III reports the vesting of restricted stock units and subsequent share transactions.
Summary
- On February 11, 2025, George A. Samuel III, General Counsel of Lineage Cell Therapeutics, Inc., reported transactions involving common shares and restricted stock units (RSUs).
- 6,076 common shares were acquired due to the vesting of RSUs granted on February 11, 2022.
- 2,440 shares were withheld by the issuer to satisfy tax obligations related to the vesting of the RSUs at a price of $0.65 per share.
- Following these transactions, Samuel directly owns 25,820 common shares and 6,075 RSUs.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, which carries a neutral sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which is a normal part of corporate governance and regulatory compliance. It provides transparency into the actions of company executives regarding their holdings of company stock.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects insider activity related to compensation.
Key Dates
| Date | Description |
|---|---|
| February 11, 2022 | Grant date of 24,303 Restricted Stock Units (RSUs) |
| February 11, 2023 | First vesting date of RSUs (approximately 25%) |
| February 11, 2024 | Second vesting date of RSUs (approximately 25%) |
| February 11, 2025 | Date of reported transactions: vesting of 6,076 RSUs and tax withholding of 2,440 shares |
| February 11, 2026 | Final vesting date of RSUs (approximately 25%) |
| February 12, 2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.